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Background: Mitochondrial dysfunction participates in the progression of several pathologies. Although there is
increasing evidence for a mitochondrial role in liver disease, little is known about its contribution to hepatic stellate
cell (HSC) activation. In this study we investigated the role of mitochondrial activity through mild uncoupling
during in vitro activation of HSCs.
Methods: Cultured primary human and mouse HSCs were treated with the chemical uncouplers FCCP and
Valinomycin. ATP levels were measured by luciferase assay and production of reactive oxygen species was
determined using the fluorescent probe DCFH-DA. Possible cytotoxicity by uncoupler treatment was evaluated by
caspase 3/7 activity and cytoplasmic protease leakage. Activation of HSCs and their response to the pro-fibrogenic
cytokine TGF-β was evaluated by gene expression of activation markers and signal mediators using RT-qPCR.
Proliferation was measured by incorporation of EdU and protein expression of α-smooth muscle actin was analyzed
by immunocytochemistry and western blot.
Results: FCCP and Valinomycin treatment mildly decreased ATP and reactive oxygen species levels. Both
uncouplers increased the expression of mitochondrial genes such as Tfam and COXIV while inducing morphological
features of quiescent mouse HSCs and abrogating TGF-β signal transduction. Mild uncoupling reduced HSC
proliferation and expression of pro-fibrogenic markers of mouse and human HSCs.
Conclusions: Mild mitochondrial uncoupling inhibits culture-induced HSC activation and their response to pro-
fibrogenic cytokines like TGF-β. These results therefore suggest mitochondrial uncoupling of HSCs as a strategy to
reduce progression of liver fibrosis.
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Hepatic stellate cells (HSCs) are liver pericytes, located
between hepatocytes and sinusoidal endothelial cells,
participating in different aspects of liver physiology, with
a fundamental function in vitamin A metabolism [1].
HSCs are extensively studied due to its role as the major
extracellular matrix producing cell upon hepatic injury,
playing a key role in the progression of chronic liver dis-
eases. In the healthy liver it presents a so-called quies-
cent phenotype, containing lipid droplets rich in retinol
and with a balanced extracellular matrix production.
Upon chronic liver injury HSCs activate, a process where
the cell loses its quiescent phenotype and acquires an* Correspondence: lvgrunsv@vub.ac.be
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distribution, and reproduction in any mediumactivated myofibroblastic one. This phenotype presents a
high proliferation rate, produces large amounts of extra-
cellular matrix and inflammatory cytokines, stimulating
a positive feedback of inflammatory cell recruitment and
collagen deposition [2].
Mitochondria are well established contributors to alco-
hol induced liver disease. For instance, chronic alcohol
intake reduces ATP levels in hepatocytes through
decreased translation of mitochondrial proteins or dam-
aging mitochondrial DNA, further increasing cell dam-
age [3,4]. Recently, mitochondria activity has also been
recognized as a possible factor in the development of
non-alcoholic fatty liver disease (NAFLD) [5]. One of
the first links between NAFLD and mitochondria
disturbance came from studies showing that obesity
induces the expression of uncoupling proteins intral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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gradient and hepatic ATP levels [6]. Reduced ATP levels
can sensitize and induce hepatocyte apoptosis and aggra-
vate liver injury [5].
Even though mitochondrial uncoupling and ATP de-
pletion is associated with different pathologies, several
studies indicate that mild uncoupling, a modest decrease
in ATP levels, can elicit a number of physiological benefi-
cial effects when applied to diseases related to obesity,
such as diabetes and NAFLD. For example, chemical un-
couplers, molecules that stimulate the leakage of protons
through the mitochondrial inner membrane, are known
to induce mitochondrial biogenesis, a process that ame-
liorates diabetes type 2 [7]. Mild mitochondrial un-
coupling also inhibits lipid accumulation in adipocytes,
indicating such mechanism as an appealing anti-obesity
strategy [8]. Interestingly, mild chemical uncoupling can
mimic the effects of calorie restriction, increasing life
span and reducing reactive oxygen species (ROS) levels
in mice [9]. Although the consequences of mitochondrial
activity have been extensively studied in hepatocytes,
little is known about its role in HSC physiology. We
studied the effect of mild mitochondrial uncoupling in
HSCs using the two different chemical uncouplers Car-
bonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP)
and Valinomycin. We show that mild chemical uncoup-
ling is able to reduce several aspects of HSC activation
indicating that HSC mitochondrial metabolism may be a
new target in the prevention of liver fibrosis.
Methods
Isolation of mouse and human hepatic stellate cells
Animals were used in accordance with institutional eth-
ical guidelines. The mouse HSC isolation method, from
approximately 20 week old male mice (30 grams), used
in this study was previously described [10]. Human
HSCs were isolated as follows: human liver non-
parenchymal cells were obtained from the left liver seg-
ment originating from a healthy cadaveric donor. These
cells were obtained after two step collagenase perfusion
of the liver segment, filtration and two low speed centri-
fugations of the cell suspension [11]. Next, human HSCs
were isolated by nycodenz (Myegaard, Oslo, Norway)
gradient centrifugation. For protein analyzes, 250 × 103
human HSCs were plated in 10 cm2 dishes, while
40 × 103 and 20 × 103 were plated in 6 well and 24 well
plates for RNA and proliferation analyzes, respectively.
The protocol and experiments were approved by the
ethical committees of the St-Luc Hospital and faculty of
Medicine of Université Catholique de Louvain.
After isolation, human and mouse cells were cultured in
Dulbecco’s modified Eagle’s medium with 10% fetal bovine
serum at 37°C, in a humidified atmosphere with 5% CO2.
Treatment with chemical uncouplers or DMSO as avehicle was performed from day one of culture and after
every two days, until cells were collected for the different
assays. Bright field images were taken with an Axioskop
light microscope (Carl Zeiss, Zaventem, Belgium).
RNA expression
After treatment with uncouplers and transforming
growth factor-β (TGF-β) (R&D Systems), total RNA was
extracted using the RNeasy Mini-kit (Qiagen, Hilden,
Germany). RNA was reverse-transcribed using the
RevertAid™ Premium Reverse Transcriptase (Fermentas,
St. Leon-Rot, Germany), performed at 25°C for 10 min-
utes and at 37°C for 40 minutes. For human HSCs,
MaximaW SYBR green qPCR Master Mix (Fermentas)
was used. For the semi-quantitative PCR of mouse HSCs
we used an Applied Biosystems 7500 Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA). Pri-
mers (view Table 1 for details) were produced by Invitro-
gen (Paisley, UK) and probes by Roche (universal probe
library, Mannheim, Germany). A 2x Maxima Probe
qPCR Master Mix was used (Fermentas, St. Leon-Rot,
Germany) to analyze gene expression as described previ-
ously [12].
Western blotting
Cells were exposed to lysis buffer (170 mM NaCl, 10 mM
EDTA, 50 mM Tris pH 7.4, 50 mM NaF, 0.2 mM dithio-
threitol and 0.5% NP-40) plus protease and phosphatase
inhibitors. Protein concentration was measured using a
bicinchoninic acid (BCA) determination kit (Pierce Chem-
ical Co., Rockford, IL, USA). Ten microgram of protein
was separated on 12% Tris–glycine SDS-Polyacrylamide
gels and transferred onto polyvinyldifluoride (PVDF)
membranes (Amersham Biosciences, Little Chalfont, UK)
using a semidry blotting apparatus (ApolloTM, Continental
Lab Products, San Diego, CA, USA). Following, mem-
branes were blocked in 5% milk in TBS-Tween. After
overnight incubation with primary antibodies at 4°C (anti-
α-smooth muscle actin, 1/1000; anti-β-actin, 1/10000,
both from Sigma, St Louis, MO, USA) and 1 hour incuba-
tion with horseradish peroxidase conjugated secondary
antibodies (1/20000) (Dako, Glostrup, Denmark), proteins
were visualized with the ECL chemiluminescence detec-
tion system (Pierce Chemical Co.). Densitometry analysis
was performed using Image J.
Immunocytochemistry
Freshly isolated mouse and human HSCs were cultivated
on glass cover slips in a 24 well plate and fixed with 4%
paraformaldehyde for 10 minutes. Cells were permeabi-
lized by 0.1% Triton-X 100 (in PBS with 1% bovine
serum albumin) for 30 minutes followed by washing.
Mouse HSCs were incubated with monoclonal antibody
against α-Smooth Muscle actin (α-SMA) coupled with
Table 1 Primer sequences, probes and accession numbers of transcripts, used for RT PCR quantification
Gene Primers sequence (Left primer/Right primer) Probe GenBank accession number Product lenght
18S 5′-aaatcagttatggttcctttggtc-3′/ 55 AY_248756 67
5′gctctagaattaccacagttatccaa-3′
PGC1α 5′- cagtcgcaacatgctcaag-3′/ 6 NM_008904 73
5′- tggggtcatttggtgactct-3′
Tfam 5′- caaaggatgattcggctcag-3′/ 97 NM_009360 92
5′- aagctgaatatatgcctgcttttc-3′
CoxIV 5′- tcactgcgctcgttctgat-3′/ 7 NM_37829.1 67
5′- cgatcgaaagtatgagggatg-3′
Ndufs7 5′- gtggtgaccaagctggatg-3′/ 104 NM_029272 67
5′- cgaaggtcataggccacag-3′
HO-1 5′- gtcaagcacagggtgacaga-3′/ 4 NM_010442 77
5′- atcacctgcagctcctcaaa-3′
Smad6 5′- gttgcaacccctaccacttc -3′/ 70 NM_008542 76
5′- ggaggagacagccgagaata -3′
Smad7 5′- acccccatcaccttagtcg -3′/ 63 NM_001042660 75
5′- gaaaatccattgggtatctgga -3′
α-SMA 5′-ccagcaccatgaagatcaag-3′/ 58 NM_007392 70
5′-tggaaggtagacagcgaagc-3′
Pdgfrβ 5′-tgcagagacctcaaaaggtg-3′/ 63 NM_008809.1 112
5′- cctgatcttcctcccagaaa-3′
Procol1a1 5′-acctaagggtaccgctgga-3′/ 19 NM_007742 97
5′-tccagcttctccatctttgc-3′
α-SMA* 5′-ctgttccagccatccttcat-3′/ NM_001141945 70
5′-tcatgatgctgttgtaggtgg-3′
PROCOL1A1* 5′-gacacagaggtttcagtgg-3′/ NM_000088.3 264
5′-cacccttagcaccaacag-3′
18S* 5′-aagacggaccagagcgaaag-3′/ K03432 98
5′-tcggaactacgacggtatct-3′
PDGFR-β* 5′-cccttatcatcctcatcatgc-3′/ NM_002609.3 60
5′-ccttccatcggatctcgtaa-3′
18S 18S ribosomal RNA, PGC1 α Peroxisome proliferative activated receptor gamma, coactivator 1α, Tfam Transcription factor A, mitochondrial, CoxIV Cytochrome
c oxidase subunit IV, Ndufs7 NADH dehydrogenase (ubiquinone) Fe-S protein 7, HO-1 Heme oxygenase-1, Smad6 MAD homolog 6, Smad7 MAD homolog 7, α-SMA
α-smooth muscle actin, Pdgfrβ Platelet-derived growth factor receptor β, Procol1a1 Procollagen 1a1. * primers for human samples.
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anti-α-SMA (both from Sigma-Aldrich, St. Louis, MO,
USA), at 4°C, overnight. After washing with PBS, human
HSCs were incubated with secondary antibody conju-
gated with Alexa 488 (1:300) (Molecular Probes, Eugene,
USA) for 1 hour at room temperature. Following wash-
ing and mounting with ProLongW Gold antifade reagent
with DAPI (Invitrogen), cells were analyzed by fluores-
cent microscopy (Carl Zeiss, Zaventem, Belgium).
Measurement of ROS
Intracellular ROS levels were determined by measuring
the fluorescence of 2′,7′- dichlorofluorescein diacetate(DCFH-DA) as described previously [10]. In experiments
using FCCP and Valinomycin (purchased from Sigma-
Aldrich, St. Louis, MO, USA), cells were pre-incubated for
the indicated time points with uncouplers. Cell samples
were analyzed by using a fluorometer (Wallac 1420 Victor
multilabel counter, Wallac Oy, Turku, Finland) with
485 nm excitation and 535 nm emission wavelenghts.
Viability assay
Cell toxicity and apoptosis induction upon mitochon-
drial uncoupler treatment was measured using the
CytoTox-Fluor™ Cytotoxicity Assay and Caspase 3/7
Assay (Promega, Madison, USA) as indicated in the
Guimarães et al. BMC Gastroenterology 2012, 12:68 Page 4 of 12
http://www.biomedcentral.com/1471-230X/12/68manufactures protocol. In brief, one thousand human or
mouse HSCs were plated in dark 96 well plates and trea-
ted with increasing concentrations of FCCP, Valinomycin
or cycloheximide (Sigma-Aldrich). After 2 and 24 hours,
cells were loaded with the cytotoxicity fluorescent mar-
ker bis-alanylalanyl-phenylalanyl-rhodamine 110 and
incubated at 37°C for 30 minutes. Following, fluores-
cence was quantified (Wallac 1420). Subsequently, cells
were lysed and loaded with a luminogenic caspase-3/7
substrate and incubated for more 30 minutes at room
temperature, followed by quantification of light emission
as a function of caspase 3/7 activity.
Cell proliferation assay
Cell proliferation was analyzed by measuring DNA syn-
thesis with the Click-it EdU Cell Proliferation Assay Kit
(Invitrogen). 3,750 cells per cm2 were plated in the pres-
ence or absence of FCCP or Valinomycin in combination
with Tin protoporphyrin IX dichloride (SnPP) (Tocris Bio-
science, USA) from the first day of culture. After 24 hours,
EdU labeling was initiated. After 18 or 48 hours, for
human and mouse HSCs respectively, cells were formalin
fixed and visualization of the EdU incorporation was
obtained according to the manufacturer’s instructions.
ATP levels measurement
ATP levels were determined using the ATP Determin-
ation Kit (Invitrogen). Briefly, 3000 cells/well were plated
in white 96 well plates (Sigma, St. Louis, MO, USA).
After two days in culture, cells were treated with FCCP
and Valinomycin for 24 hours, followed by ATP deter-
mination as determined by manufacturer’s instructions.
Statistical analysis
Statistical analyzes was performed using SPSS 16.0 (SPSS
Inc., Chicago, USA). Data are expressed as mean ± stand-
ard mean. Differences among groups were analyzed for
statistical significance by one-way ANOVA followed
by Tukey. Results were considered significant when
p < 0.05. All data shown are representative results of at
least three independent experiments.
Results
Chemical uncoupling reduces ATP and ROS levels in HSCs
while inducing genes involved in mitochondrial
biogenesis
We determined whether FCCP and Valinomycin were
able to reduce cellular ATP levels in freshly isolated
mouse HSCs, one of the main features of chemical un-
coupling. As shown in Figure 1A, 24 hours treatment
with either FCCP or Valinomycin, two mitochondrial
uncouplers with different modes of action, reduced 30%
of ATP levels when compared to control cells. Next, we
evaluated if uncouplers can modulate ROS, as they playa major role during HSC activation stimulating several
pathways related to the activation process [13]. After 30
minutes, FCCP and Valinomycin reduced ROS levels to
50% and 80% of control cells respectively (Figure 1B).
Interestingly, while FCCP shows a time dependent effect,
Valinomycin shows no time dependent decrease in ROS
levels, inducing a continuous reduction up to 24 hours.
Following, we studied the effect of HSC uncoupling on
genes related to mitochondrial biogenesis. These genes
are stimulated when energy demand is high and have
been shown to decrease ROS production and oxidative
cell damage [14]. Peroxisomal proliferator activator
receptor-γ coactivator-1α (Pgc-1α) is a regulator of mito-
chondrial biogenesis, interacting with several transcrip-
tional factors, including mitochondrial transcription
factor A (Tfam), a master regulator of mitochondrial
biogenesis [15]. As shown on Figure 1C, treatment with
FCCP and Valinomycin increased about 15 and 10 times
the expression of Pgc-1α, respectively. Uncouplers also
increased the expression of Tfam, NADH dehydrogenase
[ubiquinone] iron-sulfur protein 7 (Ndufs7) and cyto-
chrome c oxidase subunit IV (CoxIV), the last two being
genes that encode proteins from the electron transport
chain (Figure 1D). These results indicate that chemical
uncoupling leads to mild reduction in ATP levels and re-
duction in ROS levels while stimulating transcription of
mitochondrial biogenesis related genes in HSCs.Chemical uncouplers reduce the expression of pro-
fibrogenic genes in HSCs
HSC activation is characterized by a phenotypic trans-
formation from a small, lipid droplet containing cell, to
a myofibroblastic phenotype, during which the cell loses
its lipid droplets and acquires a large body size. The cell
morphology of primary mouse HSCs treated for 7 days
with chemical uncouplers was similar to that of freshly
isolated quiescent HSCs (Figure 2A). As shown in the
inserts, uncoupler treated cells presented a small round
body size while control cells showed the typical activated
myofibroblastic phenotype after 7 days of cell culture.
HSC activation is accompanied by the increased ex-
pression of pro-fibrogenic genes that are involved in sev-
eral characteristics of the myofibroblastic HSC such as
cell contraction and collagen deposition (Figure 2B, left
graph). Uncoupler-treated cells showed a reduction of
approximately 80% in the expression of α-SMA, a stand-
ard marker of HSC activation, and Pdgfrβ, a receptor
involved in HSC proliferation (Figure 2B, right graphic).
Next, we evaluated by immunohistochemistry if α-SMA
protein expression was reduced in mouse HSCs treated
with FCCP or Valinomycin. As seen in Figure 2C, α-
SMA protein expression is down regulated by both
uncoupler treatments.
Figure 1 FCCP and Valinomycin reduce HSC ATP levels, ROS production and stimulate mitochondrial biogenesis related genes. (A) Cells
were treated with 5 μM of FCCP or Valinomycin for 24 hours and ATP levels were measured using a luciferase based ATP determination kit. (B)
ROS levels were analyzed in mHSCs treated for different time points with chemical uncouplers by DCF fluorescence. HSCs were treated with
5 μM of FCCP or Valinomycin for 7 days and the expression of genes involved in mitochondrial biogenesis PGC-1α (C), Tfam, Ndufs7 and CoxIV
(D) were analyzed by RT-qPCR. * indicates P< 0.05 compared to control groups. Data are expressed as means of 3 independent
experiments ± SEM.
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effects or apoptosis
In order to test whether the concentrations of uncou-
plers used to inhibit HSC activation could be eliciting
cytotoxicity, we treated cells with a wide concentration
range of FCCP and Valinomycin and analyzed a possible
induction of necrosis by addition of a fluorescent sub-
strate of cytoplasmic endopetidases. As demonstrated in
Figure 3A, FCCP and Valinomycin did not elicit necrosis
on any concentration tested. Actually, FCCP and Valino-
mycin protected against cell death on most tested con-
centrations. Additionally, we observed no increase in
apoptosis, as measured by caspase 3/7 activity, even with
concentrations 10–20 fold higher than the one used to
inhibit HSC activation (Figure 3B).
FCCP inhibits HSC proliferation through activation of
heme-oxygenase 1
HSC proliferation is characteristic of HSC activation and a
key feature in the progression of liver fibrosis. Hence, we
investigated whether chemical uncoupling could reducecell proliferation in HSCs. FCCP and Valinomycin treat-
ment drastically decreased DNA incorporation of EdU, a
BrdU analogue (Figure 4A). While control cells showed
about 30% EdU positive cells during in vitro activation,
FCCP and Valinomycin treated cells showed only 8% EdU
positive cells, indicating less proliferation (Figure 4B).
Heme oxygenase 1 (HO-1) is the rate limiting enzyme
in the degradation of heme groups and decreases cell pro-
liferation when induced during HSC activation [16].
Therefore, we were interested in studying its expression
during culture induced activation and its possible partici-
pation in the effect of both chemical uncouplers. HO-1
gene expression is down regulated during in vitro HSC ac-
tivation and its expression can be rescued by FCCP and
Valinomycin treatment (Figure 4C and D, respectively).
To test if HO-1 plays a role in the anti-proliferative effect
of the uncouplers we co-treated cells with Sn-
protoporphyrin IX (SnPP, 5 μM), an inhibitor of HO-1.
Co-treatment partially abrogated FCCP inhibition of pro-
liferation (Figure 4A and 4B). Curiously, the observed
Valinomycin effect was not affected by SnPP co-treatment,
Figure 2 FCCP and Valinomycin inhibit the expression of HSC pro-fibrogenic genes. (A) Bright field images of mHSCs treated with FCCP
(5 μM) or Valinomycin (5 μM) every two days for a period of seven days. qHSCs and aHSCs indicate quiescent and activated HSCs respectively.
Dashed lines indicate the blow-up of area in inserts. (B) Expression of pro-fibrogenic genes during HSC activation in vitro and effect of uncoupler
treatment, left and right graphics respectively. Mouse HSCs were treated for seven days with FCCP (5 μM) or Valinomycin (5 μM) and after this
period mRNA levels of the indicated genes were analyzed by RT-qPCR. (C) α-SMA protein expression in cells treated with chemical uncouplers.
Isolated mouse HSCs were cultivated on cover slips for 7 days and then fixed with 4% formaldehyde and stained with α-SMA antibodies.
* indicates P < 0.05 compared to control groups. Data are expressed as means of 3 independent experiments ± SEM.
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proliferative effect of this chemical uncoupler.
Induction of pro-fibrotic genes by TGF-β is inhibited by
chemical uncoupling
TGF-β signalling induces several pro-fibrogenic genes
in HSCs, participating in the activation process andliver fibrosis. Mitochondrial uncoupling is able to in-
hibit several signalling pathways in different cell types;
hence we tested if mitochondrial uncoupling could
affect TGF-β signalling in HSCs. A 24 hour treat-
ment of 2 day old HSCs with TGF-β induced the
expression of α-SMA, Procollagen 1a1 and Pdgfrβ,
while in cells co-treated with Valinomycin and FCCP
Figure 3 Chemical uncoupling does not induce cytotoxicity on concentrations that inhibit HSC in vitro activation. (A) Cytotoxic effect of
mitochondrial uncouplers, as measured by fluorescence of bis-alanylalanyl-phenylalanyl-rhodamine 110, a peptide substrate of cytoplasmic
peptidases. Insert shows cells treated with cycloheximide as positive control (B) Caspase 3/7 activity after treatment of cells with different
concentrations of Valinomycin and FCCP on different time points. Enzyme activity was measured as described in material and methods.
* indicates P< 0.05 compared to control group.
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(Figure 5A).
In order to analyze whether uncouplers directly affect
TGF-β signalling, we studied if early immediate respon-
sive genes for TGF-β, namely Smad6 and 7, were also
being inhibited. As shown in Figure 5B, while TGF-β
alone induced the expression of both genes after 2 hours
of treatment, FCCP and Valinomycin inhibited such up-
regulation, suggesting that both uncouplers affect TGF-β
signalling.
Mitochondrial uncouplers reduce activation of human
HSCs
We next evaluated if mitochondrial uncoupling was also
able to reduce activation of primary human HSCs. First,
we tested if human derived HSCs presented any cytotox-
icity upon uncoupler treatment. High concentrations, ten-
fold higher than the one used to inhibit HSC activation,
did not elicit increased cytotoxicity as measured by leakageof cytoplasmic peptidases and induced activation of cas-
pase 3/7 only after 24 hours treatment (Additional file 1:
Figure S1). Secondly, as shown on Figure 6A, both uncou-
plers induce a robust decrease in the expression of pro-
fibrogenic genes after 5 days of treatment. A marked in-
hibition of α-SMA protein expression was also observed
for both treatments (Figure 6B, C). As with primary mouse
HSCs, we observed a decrease in the incorporation of EdU
in FCCP and Valinomycin treated human HSCs
(Figure 6D), indicating a decrease in cell proliferation.
These results suggest that mitochondrial uncoupling
cannot only reduce culture induced activation of mouse
HSCs, but also reduces the fibrogenic phenotype of human
activated HSCs.
Discussion
Patients with NAFLD present mitochondrial ultrastruc-
tural alterations that might reflect mitochondrial im-
pairment and subsequent hepatocyte apoptosis [17].
Figure 4 (See legend on next page.)
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Figure 4 FCCP inhibits HSC proliferation through HO-1. (A) Representative images of cells stained with DAPI (blue fluorescence, left column)
and EdU, as a measurement of DNA synthesis (green fluorescence, right column) at day 5. Cells were treated for 5 days with uncouplers (5 μM of
each) alone or in combination with the heme-oxygenase inhibitor SnPP as indicated. (B) Quantification of proliferation (EdU positive) as
percentage of DAPI positive cells visualized in (A). (C) HO-1 gene expression determined by RT-qPCR during in vitro activation of primary mouse
HSCs and comparing 7 day old control cells versus cells treated for 7 days with FCCP or Valinomycin (D). Data are expressed as means of 3
independent experiments ± SEM.
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drial role during liver disease, few studies have focused
on the role of this organelle during HSC activation
[18,19]. To our knowledge, this is the first demonstra-
tion that mild mitochondrial uncoupling can reduce sev-
eral aspects of HSC activation.
Mitochondria can elicit cell signalling and influence
cell function by adapting metabolism, altering cell re-
sponse to cytokines and nuclear gene expression [20].
Although initially counter intuitive, several studies indi-
cate that uncoupling of the mitochondrial electron
transport chain can elicit beneficial cell adaptations andFigure 5 FCCP and Valinomycin inhibit TGF-β signaling in 2 day
old mHSCs. (A) Expression of pro-fibrogenic genes in cells treated
for 24 hours with 5 μM of FCCP and Valinomycin or together with
TGF-β (10 ng/mL) as indicated. (B) Expression of TGF-β early
immediate genes Smad6 and Smad7 on HSCs treated for 2 hours
with TGF-β. * indicates P< 0.05 compared to control groups and
** indicates P< 0.05 compared to TGF-β group. Data are expressed
as means of 3 independent experiments ± SEM.improve several pathologies. Heart ischemia/reperfusion
detrimental effects can be ameliorated through pre-
conditioning with mild uncoupling using chemical
uncouplers while studies on mice show that uncoupler
treatment can increase life span, reduce oxidative stress
and improve insulin levels [21]. Remarkably, a study by
Rohas et al. has shown that once mild uncoupling is set,
cells trigger a compensatory mechanism where PGC-1α
is activated and orchestrate a signalling cascade to com-
pensate the reduction in ATP levels [22]. We also ob-
serve an increase in PGC-1α expression during HSC
mild uncoupling and a protective effect against cell ne-
crosis and apoptosis in both human and mouse derived
HSCs.
ROS and consequent oxidative stress participate in
HSC activation through several mechanisms such as
glutathione depletion and activation of transcription fac-
tors [23]. Indeed, the collagen type I promoter can be
regulated by ROS generation in HSCs, demonstrating a
fundamental role for oxidative stress in liver fibrosis per-
petuation [24]. We observed a decrease in ROS levels in
cells treated with uncouplers, suggesting ROS reduction
as one possible mechanism by which these molecules in-
hibit HSC activation. Additionally, this result also indi-
cates that treatment with FCCP and Valinomycin
induces only mild uncoupling, since harmful uncoupling
is associated with high amounts of ROS and oxidative
stress [25,26]. Curiously, FCCP and Valinomycin show
different antioxidant efficiencies. Valinomycin had a
stable and less efficient effect on reducing ROS levels,
while FCCP reduced ROS drastically after 30 minutes,
reaching control levels after 24 hours. FCCP and Valino-
mycin uncouple mitochondria by different mechanisms.
While FCCP is a proton mobile carrier that acidifies the
mitochondrial matrix, Valinomycin acts as a specific po-
tassium ionophore leading to alkalinisation of the mito-
chondrial matrix. This different effect on matrix pH can
influence the dissimilar modulation of ROS levels [27].
Since both chemical uncouplers affect ATP levels by the
same extend, it also indicates that the mode by which
they affect matrix pH does not influence the net result
on mitochondrial uncoupling.
Transcriptional regulation by the so-called adipogenic
transcription factors is essential to keep HSC quiescence
and has been shown to, once stimulated, inhibit several



























































Figure 6 Mitochondrial uncouplers reduce activation markers and proliferation of human derived HSCs. (A) Human activated HSCs
(passage 7) were treated for 5 days with FCCP or Valinomycin (10 μM, both compounds) followed by analysis of mRNA levels of pro-fibrogenic
genes by RT-qPCR. Activated human HSCs treated for 5 days with mitochondrial uncouplers present reduced α-SMA protein expression as
observed by western blot (B) and immunocytochemistry (C). Numbers below Figure B represent densitometry values of α-SMA compared to
control and normalized by β-Actin levels. (D) Representative images of cells stained with DAPI (blue fluorescence, left column) and EdU, as a
measurement of DNA synthesis (green fluorescence, right column) at day 5. (B) Quantification of proliferation (EdU positive) as percentage of
DAPI positive cells visualized in (D).
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ation similarly act on HSC activation [29]. Brown adipo-
cytes also share analogous signalling pathways during
differentiation, but opposite to white adipocytes, theypresent small disperse lipid droplets in the cytoplasm
and activate mitochondrial uncoupling when thermo-
genesis is needed. We show that chemical uncoupling
inhibits HSC activation and consequently stimulates the
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http://www.biomedcentral.com/1471-230X/12/68maintenance of the quiescent phenotype. Curiously,
treatment of white adipocytes with chemical uncouplers
induces the opposite of what is seen in HSCs, stimulating
de-differentiation, (i.e. loss of lipid droplet and inducing
a fibroblastic phenotype) [8]. Moreover, AMP-activating
kinase (AMPK), a kinase with a main role in maintaining
cellular energy levels, induces differentiation of brown
adipocytes when chronically activated, while it inhibits
the differentiation of white adipocytes [30]. In HSCs,
AMPK inhibits several aspects of HSC activation and
stimulates quiescent characteristics [31]. Together, these
data and the results observed in this study indicate that
the HSC activation process shares analogous signalling
pathways with the differentiation of brown adipocytes,
cells that present mitochondrial uncoupling activity and,
more importantly, a lipogenic phenotype similar to the
one of quiescent HSCs.
We show that different aspects of human and mouse
HSC activation such as α-SMA expression and prolifera-
tion are inhibited by chemical mitochondrial uncoupling.
One important aspect of activated HSC is the capacity to
proliferate and consequently aggravate chronic liver in-
jury. HO-1, an enzyme involved in the metabolism of
heme, can reduce HSC proliferation mainly due to the
production of bilirubin, an antioxidant end product of
heme group degradation [16]. Curiously, both uncouplers
inhibit the down regulation of HO-1 seen during ac-
tivation, but HO-1 is only responsible for the anti-
proliferative effect of FCCP and not Valinomycin, as
shown using the HO-1 inhibitor SnPP. It has been
reported that Valinomycin is able to inhibit the prolifera-
tion of different cell lines, although the mechanism is still
not fully understood [32]. Our results show that, in gen-
eral, uncoupling can inhibit HSC proliferation, but the
mechanism diverges depending on the mode of mito-
chondrial uncoupling.
TGF-β plays an essential role during liver fibrosis, and
has been intensely investigated as a target for therapy.
This cytokine activates HSC in vivo, and TGF-β KO
models have shown a dramatic reduction in α-SMA
positive cells in liver fibrosis with a consecutive decrease
in collagen deposition [33]. In this study we observed an
increase in the expression of several fibrogenic genes
when HSCs were treated with TGF-β which was com-
pletely abrogated by co-treatment with chemical uncou-
plers. The inhibition of TGF-β induced early-immediate
genes Smad6/7 by the uncouplers suggests a direct influ-
ence on TGF-β signalling. Although it is not clear how
mild mitochondrial uncoupling can influence TGF-β sig-
nalling, it is known that this cytokine can induce the re-
lease of mitochondrial calcium stores and that this
process is necessary for the activation of protein kinases
and downstream signalling of TGF-β [34]. Chemical un-
coupling can influence calcium release from mitochondria[35] and therefore might influence TGF-β signalling
through modulation of mitochondrial calcium stores.
Intriguingly, the observations in this study add a new
perspective to the action of some molecules that are
already known to inhibit HSC activation. For example,
curcumin has been shown to be a powerful mitochon-
drial uncoupler in the same concentration range known
to inhibit HSC fibrogenic features [36,37].
Conclusion
The present study shows, for the first time, that mild
mitochondrial uncoupling can inhibit HSC activation.
Importantly, we also observed a reduction in fibrogenic
features of human derived HSCs. Contrarily to mouse
HSCs, which were treated with FCCP and Valinomycin
still at the quiescent phenotype, the human HSCs used
in this study presented an activated phenotype when
treated (passage 7). Nonetheless, we still observed a de-
crease in fibrogenic features on both gene and protein
levels. These last results show that mild mitochondrial
uncoupling, additionally to its capacity to inhibit the first
steps of HSC activation, is able to induce a decrease in
activation features of already myofibroblastic HSCs. This
is an important characteristic when considering possible
applications in the treatment of liver fibrosis. In sum-
mary, we show that mild mitochondrial uncoupling can
inhibit several aspects of HSC activation and indicates
HSC mitochondrial metabolism as a possible new target
for liver fibrosis therapy.
Additional file
Additional file 1: Figure S1. Mitochondrial uncouplers show no
cytotoxicity at low concentrations. (A) Cytotoxic effect of mitochondrial
uncouplers on human HSCs, as measured by fluorescence of bis-
alanylalanyl-phenylalanyl-rhodamine 110, a peptide substrate of
cytoplasmic peptidases. (B) Caspase 3/7 activity after treatment of cells
with different concentrations of Valinomycin and FCCP on different time
points. Enzyme activity was measured as described in material and
methods. * indicates P< 0.05 compared to control group.
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